Additional file 1 of Characteristics of acute kidney injury and its impact on outcome in patients with acute-on-chronic liver failure

Additional file 1: Comparison of clinical characteristics between training cohort and validation cohort

Drug susceptibility of rtM204Q and rtM204I mutants and wild-type strain.

<p>EC₅₀, 50% effective concentration of drug (µ mol/L).</p

Assessment of HBV natural replication capacity of HBV strains isolated from patient 1.

<p>The relative replication capacities of mutants were analyzed compared to that of wild-type strain (defined as 100%) in the absence of drug. Data are presented as mean ± standard deviation. Experiments were performed at least 3 times independently. *<i>P</i><0.05 (<i>vs</i>. wild-type strain).</p

Follow-up the clinical course of three representative patients with HBV rtM204Q mutant during antiviral treatment.

<p>The dynamic changes of serum HBV DNA and alanine aminotransferase (ALT) levels are shown along with the successive antiviral therapies for patient 1 (A), patient 4 (B), and patient 6 (C). The duration (months) of the therapies for antivirals is indicated by bars and the successfully-sequenced samples are indicated by arrows with sample (S) numbers above the graph. The dashed red and blue lines show the lower detection limit of HBV DNA and normal ALT levels, respectively. Proportions of wild-type and mutant strains in the viral reverse transcriptase domain of each sample are depicted by a series of pie-charts. ADV, adefovir dipivoxil; LAM, lamivudine.</p

Mutations by direct sequencing and clinical data of the studied patients.

<p>Mutations by direct sequencing and clinical data of the studied patients.</p

Distribution of factors significantly associated with LSM failure.

<p>Patients’ percentage distribution according to the factors associated with LSM failure is showed (A), and the significances were determined by univariate and multivariate analyses (B). Intercostal space (IS).</p

Correlation of IP-10 expression with the allele and genotype.

<p>(a) Luciferase activity in HepG2 cells transfected with promoter-reporter vectors corresponding to -201GG or AA haplotype homozygotes, respectively. The vertical axis represents the relative proportion of luciferase activity to corresponding pGL3-enhancer vectors. Data represent mean of representative data from three experiments performed in quadruplicate. <i>P</i> values were estimated by Student <i>t</i> test. (b) Expression of CXCL10 measured by quantitative SYBR PCR of RNAs purified from peripheral blood mononuclear cells of 24 patients. Columns, mean from triplicate measurements; bars, SD.</p

Frequency of LSM failure according to different diseases.

<p>LSM failure rate in 38,464 LSM examinations is overviewed (A), and Chi-square test is applied to find the unsuccessful and unreliable LSM rate differences between each disease group and the total failure rate (B). AsC, chronic asymptomatic HBV carrier; CH, chronic hepatitis; LC-1, compensated liver cirrhosis; LC-2, decompensated liver cirrhosis; ALD, alcoholic liver disease; AILD, autoimmune liver disease; DILIN, drug-induced liver injure; HCC, hepatocellular carcinoma (HCC); other includes liver transplant recipient, hepatolenticular degeneration, and Budd-chiari syndrome.</p

G-201A frequencies and odds ratio for the association with disease progression.

*<p>denotes <i>P</i><0.05; **denotes <i>P</i><0.01.</p><p>HC, healthy controls; AHB, acute hepatitis B; CHB-M, mild chronic hepatitis B; CHB-S, severe chronic hepatitis B.</p

Clinical details of the studied population.

<p>HC, healthy controls; AHB, acute hepatitis B; CHB-M, mild chronic hepatitis B; CHB-S, severe chronic hepatitis B.</p